Clinical trials: sponsored by Hoffmann-La Roche
Solid Tumors, Metastatic Melanoma
Dose Escalation Study of a PD1-LAG3 Bispecific Antibody in Patients With Advanced and/or Metastatic Solid Tumors
This is a first-in-human, open-label, multicenter, Phase I multiple-ascending dose (MAD) study of RO7247669, an anti PD-1 (programmed death-1) and LAG-3 (Lymphocyte-activation gene 3) bispecific antibody, for participants with…
- Conditions
- Solid Tumors, Metastatic Melanoma, Non-small Cell Lung Cancer, Esophageal Squamous Cell Carcinoma
- Trial name
- NCT04140500
- Testing
- RO7247669
- Where
- 25 sites in Denmark, Georgia and 7 more
- Volunteers
- 170 people
- Sponsor
- Hoffmann-La Roche
Large B-Cell Lymphoma
An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma
The purpose of this study is to compare the efficacy and safety of glofitamab in combination with polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) vs Pola-R-CHP in participants with…
- Trial name
- NCT06047080
- Testing
- Glofitamab, Polatuzumab vedotin, Rituximab
- Where
- 229 sites in United States, Argentina and 19 more
- Volunteers
- 1,130 people
- Sponsor
- Hoffmann-La Roche
Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
A Study of Atezolizumab and Trastuzumab in Combination With Capecitabine and Oxaliplatin in Patients With HER2 Positive Locally Advanced Resectable Gastric Cancer of Adenocarcinoma of Gastroesophageal Junction
This is a phase II, multicenter, randomized, open-label study designed to evaluate the efficacy and safety of perioperative trastuzumab+XELOX with / without atezolizumab in participants eligible for surgery with locally advanced…
- Trial name
- NCT04661150
- Testing
- Atezolizumab, Trastuzumab, Capecitabine
- Where
- 8 sites in China
- Volunteers
- 42 people
- Sponsor
- Hoffmann-La Roche
Ovarian Cancer
A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors
This study will evaluate the efficacy and safety of multiple biomarker-selected treatments in patients with persistent or recurrent rare epithelial ovarian, fallopian tube, or primary peritoneal tumors.
- Trial name
- BOUQUET (NCT04931342)
- Testing
- Ipatasertib, Cobimetinib, Trastuzumab Emtansine
- Where
- 41 sites in United States, Australia and 11 more
- Volunteers
- 176 people
- Sponsor
- Hoffmann-La Roche
Chronic Obstructive Pulmonary Disease
A Study to Evaluate Safety and Efficacy of Lebrikizumab in Participants With Chronic Obstructive Pulmonary Disease (COPD)
Phase II, randomized, double-blind, placebo-controlled, parallel-group clinical trial of lebrikizumab in participants with COPD and a history of exacerbations who are treated with inhaled corticosteroid (ICS) and at least one…
- Trial name
- NCT02546700
- Testing
- Lebrikizumab
- Where
- 63 sites in United States, Argentina and 7 more
- Volunteers
- 309 people
- Sponsor
- Hoffmann-La Roche
Small-Cell Lung Cancer
A Phase III, Open-Label Study of Maintenance Lurbinectedin in Combination With Atezolizumab Compared With Atezolizumab in Participants With Extensive-Stage Small-Cell Lung Cancer
Study GO43104 is a Phase III, randomized, open-label, multicenter study of lurbinectedin in combination with atezolizumab compared with atezolizumab alone administered as maintenance therapy in participants with extensive-stage…
- Trial name
- IMforte (NCT05091567)
- Testing
- Atezolizumab, Lurbinectedin, Carboplatin
- Where
- 93 sites in United States, Belgium and 11 more
- Volunteers
- 660 people
- Sponsor
- Hoffmann-La Roche
Alzheimer's Disease
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7812653 in Participants With Early Symptomatic Alzheimer's Disease (eAD)
This study aims to evaluate the safety, tolerability, immunogenicity, pharmacokinetics, and pharmacodynamics following administration of RO7812653 in participants with eAD.
- Trial name
- NCT07234942
- Testing
- RO7812653
- Where
- 12 sites in Canada, Netherlands and 3 more
- Volunteers
- 6 people
- Sponsor
- Hoffmann-La Roche
Obesity, Overweight
A Study to Assess Efficacy, Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7204239 in Combination With Tirzepatide in Participants With Obesity or Overweight With At Least One Weight-related Comorbidity
The main aim of the study is to assess the effect of RO7204239 in combination with tirzepatide, compared to placebo in combination with tirzepatide, on body weight loss after 48 weeks of treatment in adults with obesity or…
- Conditions
- Obesity, Overweight, Overweight With One Weight Related Comorbidity
- Trial name
- GYMINDA (NCT06965413)
- Testing
- RO7204239, Tirzepatide
- Where
- 35 sites in United States, Poland and 2 more
- Volunteers
- 285 people
- Sponsor
- Hoffmann-La Roche
Duchenne Muscular Dystrophy
A Gene Delivery Study to Evaluate the Safety and Expression of Delandistrogene Moxeparvovec in Participants Under the Age of Four With Duchenne Muscular Dystrophy (DMD)
This open-label, single-arm study will evaluate the safety and expression of delandistrogene moxeparvovec in participants with DMD. Participants will be in the study for approximately 264 weeks.
- Trial name
- ENVOL (NCT06128564)
- Testing
- delandistrogene moxeparvovec
- Where
- 7 sites in Belgium, France and 4 more
- Volunteers
- 13 people
- Sponsor
- Hoffmann-La Roche
Overweight, Obesity
A Study Investigating the Safety of RO7795081 and the Effect of RO7795081 on How the Body Processes Pitavastatin and Rosuvastatin in Otherwise Healthy Overweight or Obese Adult Participants
This is a randomized, investigator-and-participant-blind, placebo-controlled, fixed sequence, cross-over, Phase 1 study to investigate the safety, tolerability, and pharmacokinetics of multiple doses of orally administered…
- Trial name
- NCT06982131
- Testing
- RO7795081, Rosuvastatin, Pitavastatin
- Where
- Netherlands
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Hoffmann-La Roche
Stable Coronary Artery Disease, Healthy Volunteers
A Study to See How RO7763505 Works and How Safe it is When Given to Healthy People and People With Stable Heart Disease
This study will evaluate safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of single ascending doses (SAD) (Part 1a), multiple ascending doses (MAD) (Part 1b), and the food effect (Part 1c) of RO7763505 in…
- Trial name
- NCT07495813
- Testing
- RO7763505
- Where
- Netherlands
- Volunteers
- 196 people, healthy volunteers welcome
- Sponsor
- Hoffmann-La Roche
Duchenne Muscular Dystrophy
A Study to Assess the Efficacy and Safety of Satralizumab in Duchenne Muscular Dystrophy (DMD)
The purpose of this study is to assess the efficacy, safety, pharmacokinetics (PK) and pharmacodynamics (PD) of satralizumab, a humanized anti-interleukin-6 receptor (aIL-6R) monoclonal antibody, in ambulatory and non-ambulatory…
- Trial name
- SHIELD DMD (NCT06450639)
- Testing
- Satralizumab
- Where
- 18 sites in United States, Denmark and 4 more
- Volunteers
- 30 people
- Sponsor
- Hoffmann-La Roche
Parkinsons Disease
A Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early Parkinson's Disease
This is a multicenter, randomized, double-blind, placebo-controlled study that will evaluate the efficacy and safety of intravenous (IV) prasinezumab versus placebo in participants with Early Parkinson's Disease (PD) who are on…
- Trial name
- PADOVA (NCT04777331)
- Testing
- Prasinezumab
- Where
- 110 sites in United States, Austria and 7 more
- Volunteers
- 586 people
- Sponsor
- Hoffmann-La Roche
Solid Tumors
Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study
TAPISTRY is a Phase II, global, multicenter, open-label, multi-cohort study designed to evaluate the safety and efficacy of targeted therapies or immunotherapy as single agents or in rational, specified combinations in…
- Trial name
- NCT04589845
- Testing
- Entrectinib, Alectinib, Atezolizumab
- Where
- 112 sites in United States, Australia and 21 more
- Volunteers
- 920 people
- Sponsor
- Hoffmann-La Roche
Breast Cancer
A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy
This is a Phase III, two-arm, randomized, double-blind placebo-controlled study in participants with HER2-positive primary breast cancer who have received preoperative chemotherapy and HER2-directed therapy, including trastuzumab…
- Trial name
- Astefania (NCT04873362)
- Testing
- Atezolizumab, Trastuzumab Emtansine, Trastuzumab
- Where
- 238 sites in United States, Australia and 30 more
- Volunteers
- 1,188 people
- Sponsor
- Hoffmann-La Roche
Advanced Liver Cancers
A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver)
This is a Phase Ib/II, open-label, multicenter, randomized umbrella study in participants with advanced liver cancers. The study is designed with the flexibility to open new treatment arms as new treatments become available…
- Trial name
- MORPHEUS-LIVER (NCT04524871)
- Testing
- Atezolizumab, Bevacizumab 15 mg/kg, Tiragolumab
- Where
- 32 sites in United States, China and 5 more
- Volunteers
- 518 people
- Sponsor
- Hoffmann-La Roche
Non-Small Cell Lung Cancer
A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)
This is a phase 2/3, global, multicenter, open-label, multi-cohort study designed to evaluate the safety and efficacy of targeted therapies or immunotherapy as single agents or in combination in participants with unresectable…
- Trial name
- B-FAST (NCT03178552)
- Testing
- Alectinib, Atezolizumab, Pemetrexed
- Where
- 161 sites in United States, Argentina and 25 more
- Volunteers
- 1,000 people
- Sponsor
- Hoffmann-La Roche
Huntington's Disease
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RG6496 in Huntington's Disease
This is a first-in-human (FIH) study of RG6496 that will assess the safety and tolerability of single-ascending doses of RG6496 administered to huntington's disease gene expansion carriers (HDGECs).
- Trial name
- POINT-HD (NCT07246941)
- Testing
- RG6496
- Where
- 7 sites in Argentina, Australia and 3 more
- Volunteers
- 3 people
- Sponsor
- Hoffmann-La Roche
Neovascular Age-related Macular Degeneration, nAMD
A Study of the Efficacy, Safety, and Pharmacokinetics (PK) of the Port Delivery System With Ranibizumab (PDS) in Chinese Participants With Neovascular Age-related Macular Degeneration (nAMD)
This study will evaluate the efficacy, safety, and PK of ranibizumab 100 milligrams per milliliter (mg/mL) delivered every 24 weeks (Q24W) via the PDS implant compared with ranibizumab 0.5 milligrams (mg) delivered every 4 weeks…
- Trial name
- HUTONG (NCT05562947)
- Testing
- PDS With Ranibizumab (100 mg/mL), Ranibizumab (10 mg/mL)
- Where
- 14 sites in China
- Volunteers
- 68 people
- Sponsor
- Hoffmann-La Roche
Paroxysmal Hemoglobinuria, Nocturnal
Study to Assess Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Crovalimab in Healthy Volunteers and Participants With Paroxysmal Nocturnal Hemoglobinuria
This is a Phase I/II, first-in-human study consisting of four sequential parts and an open-label extension (OLE). The safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single doses of crovalimab will be…
- Trial name
- COMPOSER (NCT03157635)
- Testing
- Crovalimab
- Where
- 15 sites in France, Germany and 5 more
- Volunteers
- 59 people, healthy volunteers welcome
- Sponsor
- Hoffmann-La Roche
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.